Eikon Therapeutics, Inc. EIKN
6.67 USD +0.54 (+8.81%)
At closeNov 11, 2026, 5:35 PM EST
6.66 -0.01 -0.15%
After hours · Nov 11, 5:35 PM ET
6.08 Day range 6.81
5.01 52-week range 17.40
- YTD
- -55.53%
- 1 year
- -55.53%
News
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Co-Diagnostics (NASDAQ:CODX) stock moved upwards by 22.4% to $0.39 during Tuesday's pre-market session. The company's market cap stands at $2.8 million. As per the press release, Q3 earnings…
marketbeat.com Eikon Therapeutics Eyes 2027 Melanoma Trial Update, With Key Cancer Data Expected in 2029 Eikon Therapeutics NASDAQ: EIKN expects an interim analysis of its lead melanoma study in the first half of 2027 and estimates that definitive data from that trial and a lung cancer study could be…
seekingalpha.com Eikon Therapeutics, Inc. (EIKN) Presents at JP Morgan Biotech Call Series Transcript Eikon Therapeutics, Inc. (EIKN) Presents at JP Morgan Biotech Call Series Transcript
globenewswire.com Eikon Therapeutics to Participate in Multiple Investor Conferences in November MILLBRAE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to…
benzinga.com Eikon Therapeutics Announces EIK1001 Plus Pembrolizumab And Chemotherapy In First-Line, Stage 4 Non-Small Cell Lung Cancer Demonstrates Durable Effect In Combination With Standard-Of-Care, With Tolerability Profile Supportive Of Systemic Administration In An Outpatient Setting EIK1001 Clinical Update:Updated data from the open-label TeLuRide-005 trial evaluating TLR7/8 dual-agonist EIK1001 in combination with both pembrolizumab and histology-appropriate chemotherapy in…
globenewswire.com Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress MILLBRAE, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to…
benzinga.com Eikon Therapeutics Presents Initial And Updated Data For EIK1003 And Initial Data For EIK1004 And EIK1005 At ESMO 2026; Initial And Updated Cohort Data From Ongoing Phase 1/2 Study Of EIK1003 Continue To Support Potentially Differentiated Profile Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced…
globenewswire.com Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress MILLBRAE, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to…
globenewswire.com Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress Presentations to cover updates across Eikon's clinical pipeline including: Updated data from TeLuRide-005, an ongoing open-label Phase 2 trial of EIK1001, a TLR7/8 dual-agonist, plus pembrolizumab…
benzinga.com HC Wainwright & Co. Initiates Coverage On Eikon Therapeutics with Buy Rating, Announces Price Target of $23 HC Wainwright & Co. analyst Sara Nik initiates coverage on Eikon Therapeutics (NASDAQ:EIKN) with a Buy rating and announces Price Target of $23.
benzinga.com Eikon Therapeutics Files Submits Investigational New Drug Application To FDA To Evaluate EIK1006 To Treat Advanced Metastatic Prostate Cancer Eikon Therapeutics, Inc. (Nasdaq: EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced…
globenewswire.com Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer MILLBRAE, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to…
benzinga.com Alpha Buying: Follow the Money From NVIDIA and Merck Wall Street loves a good upgrade, especially when the stock has already doubled and the analyst can explain why everyone should have owned it six months ago. One place I look for ideas is the…
seekingalpha.com Eikon Therapeutics, Inc. (EIKN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Eikon Therapeutics, Inc. (EIKN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
globenewswire.com Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer MILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to…
globenewswire.com Eikon Therapeutics to Participate in Investor Conferences in September 2026 MILLBRAE, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to…
benzinga.com Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.
marketbeat.com Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004 Eikon Therapeutics NASDAQ: EIKN outlined its development strategy for selective PARP1 inhibitors and its Werner helicase inhibitor during a discussion hosted by Cantor biotech analyst Imogen…
seekingalpha.com Eikon Therapeutics, Inc. (EIKN) Discusses Advances in PARP1 Biology and Next-Generation PARP Inhibitors in Oncology Transcript Eikon Therapeutics, Inc. (EIKN) Discusses Advances in PARP1 Biology and Next-Generation PARP Inhibitors in Oncology Transcript
benzinga.com Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting strong Q4 results and positive sales guidance.
globenewswire.com Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald Chairman and Chief Executive Officer, Roger M. Perlmutter, M.D., Ph.D., will participate in a key opinion leader (KOL) event on Thursday, August 20, 2026- benzinga.com Wedbush Maintains Underperform on Eikon Therapeutics, Lowers Price Target to $4 Wedbush analyst Robert Driscoll maintains Eikon Therapeutics (NASDAQ:EIKN) with a Underperform and lowers the price target from $5 to $4.
globenewswire.com Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates MILLBRAE, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to…
benzinga.com Eikon Therapeutics Announces Selection Of Dose Of 0.60 mg/m2 To Be Employed In Future For All Patients Randomized To Receive EIK1001 In TeLuRide-006 Trial Selected 0.60 mg/m2 as the single dose for the TeLuRide-006 study going forward for patients randomized to EIK1001 treatment, in accord with a recommendation of the independent Data Monitoring…
globenewswire.com Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board MILLBRAE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to…
defenseworld.net Eikon Therapeutics, Inc.’s (NASDAQ:EIKN) Lock-Up Period Will Expire on August 4th Eikon Therapeutics' (NASDAQ: EIKN - Get Free Report) lock-up period will end on Tuesday, August 4th. Eikon Therapeutics had issued 21,177,600 shares in its IPO on February 5th. The total size of the…
benzinga.com Crude Oil Falls Sharply; US Durable Goods Orders Increase 0.3% In June US stocks mixed in midday trading, Nasdaq falls 0.48%, Dow up 0.19%, S&P 500 down 0.23%. Consumer staples up 2%, tech down 1.9%. Durable goods orders rise 0.3%.
benzinga.com Baker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks Moving Higher On Monday Dow Jones up 400 points on Monday. Baker Hughes Co (BKR) shares rise after positive earnings and technology order. Other big gainers include NIPG, FBRX, TRAX, GENI, BMNR, OMER, ASAN, EIKN, IONQ, and…- benzinga.com Eikon Therapeutics Doses First Patient In TeLurRide-008, A Phase 2/3 Registrational Study Of EIK1001 In Combination With Pembrolizumab And Histology-Appropriate Chemotherapy For Stage 4 Non-Small Cell Lung Cancer "Treating the first patient in TeLuRide-008 is a significant milestone for Eikon as we continue to advance EIK1001 in multiple indications, with the ultimate goal of delivering improved outcomes to…
globenewswire.com Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer MILLBRAE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to…
globenewswire.com Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress Presentations to cover updates across Eikon's clinical pipeline including: Updated data from TeLuRide-005, an ongoing Phase 2 trial of EIK1001, a TLR7/8 dual agonist, plus pembrolizumab and…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Pulsenmore (NASDAQ:PLSM) shares increased by 171.2% to $10.47 during Monday's pre-market session. The company's market cap stands at $25.1 million. Q32 Bio (NASDAQ:QTTB) stock rose 65.92% to…- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares moved upwards by 66.9% to $6.31 during Thursday's after-market session. The company's market cap stands at $2.1 million. INVO Fertility…
- benzinga.com Eikon Therapeutics Set To Join Russell 3000 Index, Effective June Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced…
globenewswire.com Eikon Therapeutics to Join the Russell 3000® Index Addition reflects Eikon's progress as a publicly traded company and increasing visibility within the investment community Addition reflects Eikon's progress as a publicly traded company and…
seekingalpha.com Eikon Therapeutics: Initiating Coverage With A Cautious Buy Rating Eikon Therapeutics is initiated with a cautious buy, leveraging industry-leading management and a robust oncology-focused pipeline. EIKN's ASCO data for EIK1001 in NSCLC showed a 63.1% ORR and…- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Zebra Technologies, Vishay Precision Group, Quantum Computing, Aramark And Other Big Stocks Moving Higher On Tuesday ZBRA, VSTS, AMBQ, VPG, BAK, PACS, LOT, EIKN, DDD, WEN, SIBN post significant gains on better-than-expected financial results and guidance. Peltz may take Wendy's private.
benzinga.com Wedbush Maintains Underperform on Eikon Therapeutics, Lowers Price Target to $5 Wedbush analyst Robert Driscoll maintains Eikon Therapeutics (NASDAQ:EIKN) with a Underperform and lowers the price target from $7 to $5.- benzinga.com Eikon Therapeutics Q1 EPS $(2.46) Beats $(4.07) Estimate Eikon Therapeutics (NASDAQ:EIKN) reported quarterly losses of $(2.46) per share which beat the analyst consensus estimate of $(4.07) by 39.56 percent. This is a 90.86 percent increase over losses of…
benzinga.com Domino's Posts Downbeat Q1 Results, Joins Real Brokerage And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures mixed with Dow futures down 0.1%. Domino's Pizza misses earnings expectations, shares fall 3.8%. Other stocks also decline.- benzinga.com Wedbush Reiterates Underperform on Eikon Therapeutics, Maintains $7 Price Target Wedbush analyst Robert Driscoll reiterates Eikon Therapeutics (NASDAQ:EIKN) with a Underperform and maintains $7 price target.
- benzinga.com Cantor Fitzgerald Initiates Coverage On Eikon Therapeutics with Overweight Rating Cantor Fitzgerald analyst Imogen Mansfield initiates coverage on Eikon Therapeutics (NASDAQ:EIKN) with a Overweight rating.
- benzinga.com JP Morgan Initiates Coverage On Eikon Therapeutics with Overweight Rating, Announces Price Target of $29 JP Morgan analyst Brian Cheng initiates coverage on Eikon Therapeutics (NASDAQ:EIKN) with a Overweight rating and announces Price Target of $29.
benzinga.com This NextTrip Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Wall Street analysts changed outlook on top names. For all changes, upgrades, downgrades and initiations, see analyst ratings page.- benzinga.com B of A Securities Initiates Coverage On Eikon Therapeutics with Buy Rating, Announces Price Target of $34 B of A Securities analyst Jason Zemansky initiates coverage on Eikon Therapeutics (NASDAQ:EIKN) with a Buy rating and announces Price Target of $34.
benzinga.com Mizuho Initiates Coverage On Eikon Therapeutics with Outperform Rating, Announces Price Target of $26 Mizuho analyst Joseph Catanzaro initiates coverage on Eikon Therapeutics (NASDAQ:EIKN) with a Outperform rating and announces Price Target of $26.- benzinga.com Morgan Stanley Initiates Coverage On Eikon Therapeutics with Overweight Rating, Announces Price Target of $32 Morgan Stanley analyst Sean Laaman initiates coverage on Eikon Therapeutics (NASDAQ:EIKN) with a Overweight rating and announces Price Target of $32.
- benzinga.com Wedbush Initiates Coverage On Eikon Therapeutics with Underperform Rating, Announces Price Target of $7 Wedbush analyst Robert Driscoll initiates coverage on Eikon Therapeutics (NASDAQ:EIKN) with a Underperform rating and announces Price Target of $7.
benzinga.com Wall Street Braces For IPO Boom: Goldman Says 2026 Listings Could Hit $160 Billion As Tech, AI Lead The U.S. is reportedly poised for a wave of significant IPOs, with Goldman Sachs projecting proceeds to quadruple to a record $160 billion in 2026.